Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to announce it has begun cultivating Psilocybe mushrooms, for the purpose of psilocybin production, at its 7000 square-foot Health Canada…
Last week, Compass Pathways (CMPS) commenced trading on the Nasdaq and became the first psychedelic drug company to go public on a major U.S. stock exchange. When Compass filed to go public, the deal generated substantially more interest from investors than expected. As a result, the psychedelic therapy company upsized…
Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF)(DE: MMQ), the leading drug development company for psychedelic inspired medicines, is evaluating an expanded United States investor base through an up-listing on the NASDAQ Capital Market ("NASDAQ"). As part of this up-listing strategy in the United States, MindMed has submitted an application to list its subordinate…
After Champignon Brands was issued a cease trade order from the SEC, the entire psychedelic therapy sector came under pressure and this is a trend that we have been closely following. Although we believe that investors need to conduct significant due diligence and be selective when it comes to the…
2020 has been a challenging year for the global economy and the COVID pandemic has made an impact on the mental health market. We believe that the pandemic has served as a catalyst for the psychedelic therapy market as healthcare providers and researchers seek new ways to treat debilitating mental…
Last week, Havn Life Sciences Inc. (CSE:HAVN) commenced trading on the Canadian Securities Exchange (CSE) under the ticker symbol HAVN. The biotech company has been focused on the development of standardized psychoactive compounds that are derived from plants and fungi for use in research and is an opportunity that we…
Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), is pleased to announce that it has closed its previously announced short form prospectus offering, on a best efforts basis, including the exercise of the agent's option in its entirety in the form of units of the Company (each, a "Unit"). A…
Rritual, the premium brand in the emerging functional mushroom market, announced today that it will launch its suite of premium mushroom and adaptogen enhanced elixirs this fall. Made from a proprietary blend of organic mushrooms and time-tested adaptogenic herbs, Rritual's easy-to-mix elixirs are formulated to blend into your daily wellness…
Today, we are lucky to have Doug Drysdale - CEO - of Cybin Corp. with us and appreciate you taking the time to educate our readers. Cybin is a leading Life Sciences Company focused on the development of products and protocols in the psychedelic, pharmaceutical and nutraceutical sectors. Congratulations on…
AWAKN Life Sciences Inc ("AWAKN"), the European psychedelic assisted psychotherapy company, today announces the launch of its Commercial Clinical Research Division. AWAKN's purpose is broadening access to psychedelic assisted psychotherapy and integrating these services into mainstream mental healthcare in Europe across three business divisions of Clinical Research, Therapeutic Clinics, and…
